专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011130328A1 TRAIL R2-SPECIFIC MULTIMERIC SCAFFOLDS 审中-公开
标题翻译： TRAIL R2特定多媒体文件
公开(公告)号：WO2011130328A1
公开(公告)日：2011-10-20
申请号：PCT/US2011/032188
申请日：2011-04-12
申请人： MEDIMMUNE, LLC , BACA, Manuel , THISTED, Thomas , SWERS, Jeffrey , TICE, David
发明人： BACA, Manuel , THISTED, Thomas , SWERS, Jeffrey , TICE, David
IPC分类号： C07K16/18
CPC分类号： C07K19/00 , A61K2039/505 , C07K14/001 , C07K14/78 , C07K16/1027 , C07K16/2878 , C07K16/468 , C07K2317/73 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： The present invention provides Tenascin-3 FnIII domain-based multimeric scaffolds that specifically bind to TRAIL Receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The invention further provides engineered variants with increased affinity for the target, increase stability, and reduced immunogenicity. Furthermore, the present invention is related to engineered multivalent scaffolds as prophylactic, diagnostic, or therapeutic agents, and their uses against diseases caused by cells expressing TRAIL R2, in particular to a therapeutic use against cancer.
摘要翻译：本发明提供特异性结合参与凋亡的细胞膜受体TRAIL受体2（TRAIL R2）的基于腱生蛋白-3 FnIII结构域的多聚体支架。本发明进一步提供对目标具有增加的亲和力，增加稳定性和降低的免疫原性的工程变体。此外，本发明涉及作为预防，诊断或治疗剂的工程化多价支架，以及它们对由表达TRAIL R2的细胞引起的疾病的用途，特别是抗癌治疗用途的用途。

2. 发明申请

WO2011130324A1 FIBRONECTIN TYPE III DOMAIN-BASED MULTIMERIC SCAFFOLDS 审中-公开
标题翻译：基于FIBRONECTIN III型的多基因多态性
公开(公告)号：WO2011130324A1
公开(公告)日：2011-10-20
申请号：PCT/US2011/032184
申请日：2011-04-12
申请人： MEDIMMUNE, LLC , BACA, Manuel , THISTED, Thomas , SWERS, Jeffrey
发明人： BACA, Manuel , THISTED, Thomas , SWERS, Jeffrey
IPC分类号： A61K39/395
CPC分类号： C07K19/00 , A61K2039/505 , C07K14/001 , C07K14/78 , C07K16/1027 , C07K16/2878 , C07K16/468 , C07K2317/73 , C07K2317/90 , C07K2318/20 , C07K2319/00 , C07K2319/30 , C07K2319/33 , C07K2319/70 , C07K2319/74
摘要： The present invention provides fibronectin type III (Fn3)-based multimeric scaffolds that specifically bind to one or more specific target antigen. The invention further provides bispecific Fn3-derived binding molecules that bind to two or more target antigens simultaneously, fusions, conjugates, and methods to increase the stability of Fn3-based binding molecules. Furthermore, the present invention is related to a prophylactic, therapeutic or diagnostic agent, which contains Fn3-based multimeric scaffolds.
摘要翻译：本发明提供了特异性结合一种或多种特异性靶抗原的基于纤连蛋白III（Fn3）的多聚体支架。本发明还提供了同时结合两种或多种靶抗原的双特异性Fn3衍生结合分子，融合物，缀合物和增加Fn3基结合分子稳定性的方法。此外，本发明涉及含有Fn3的多聚体支架的预防，治疗或诊断试剂。

3. 发明申请

WO2009058379A2 PROTEIN SCAFFOLDS 审中-公开
标题翻译：蛋白质组蛋白
公开(公告)号：WO2009058379A2
公开(公告)日：2009-05-07
申请号：PCT/US2008/012398
申请日：2008-10-31
申请人： MEDIMMUNE, LLC , WU, Herren , BACA, Manuel , SWERS, Jeffrey , CHACKO, Benoy
发明人： WU, Herren , BACA, Manuel , SWERS, Jeffrey , CHACKO, Benoy
IPC分类号： C40B40/10
CPC分类号： G01N33/566 , C07K14/78 , C07K16/2878 , C07K2318/20 , C07K2319/00 , C12N15/1037 , C12N15/1044
摘要： The invention provides protein scaffolds and methods of preparing, screening, engineering and using such protein scaffolds.
摘要翻译：本发明提供蛋白质支架和制备，筛选，工程和使用这种蛋白质支架的方法。

4. 发明申请

WO2006012688A1 A METHOD OF TREATING CANCER COMPRISING A VEGF-B ANTAGONIST 审中-公开
标题翻译：一种治疗包含VEGF-B拮抗剂的癌症的方法
公开(公告)号：WO2006012688A1
公开(公告)日：2006-02-09
申请号：PCT/AU2005/001152
申请日：2005-08-02
申请人： AMRAD OPERATIONS PTY LTD , NASH, Andrew , DUNLOP, Felicity, Meredith , BACA, Manuel , FABRI, Louis, Jerry , SCOTNEY, Pierre, David
发明人： NASH, Andrew , DUNLOP, Felicity, Meredith , BACA, Manuel , FABRI, Louis, Jerry , SCOTNEY, Pierre, David
IPC分类号： A61K38/18
CPC分类号： C07K16/22 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue.
摘要翻译：本发明一般涉及癌症治疗和预防领域。更具体地，本发明提供抑制癌症生长的生长因子拮抗剂，包括肿瘤和癌前组织。更具体地，本发明涉及血管内皮生长因子B的拮抗剂及其抑制癌症生长的用途，包括肿瘤组织和癌前组织。

5. 发明申请

WO2008060814A2 ANTI-IL-13Rα1 ANTIBODIES AND THEIR USES THEREOF 审中-公开
标题翻译：抗-IL-13Rα1抗体及其用途
公开(公告)号：WO2008060814A2
公开(公告)日：2008-05-22
申请号：PCT/US2007/081884
申请日：2007-10-19
申请人： MERCK & CO., INC. , CSL LIMITED , NASH, Andrew, Donald , BACA, Manuel , FABRI, Louis, Jerry , ZALLER, Dennis , STROHL, William, R. , AN, Zhiqiang
发明人： NASH, Andrew, Donald , BACA, Manuel , FABRI, Louis, Jerry , ZALLER, Dennis , STROHL, William, R. , AN, Zhiqiang
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2317/92
摘要： Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rαl through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rαl- mediated activities are also disclosed.
摘要翻译：本文公开了人IL-13受体α1的抗体拮抗剂，其通过受体胞外区的结构域3与hIL-13Rα1结合并抑制由IL-13介导的IL-13受体介导的信号传导。这些抗体尤其用于治疗或预防IL-13相关的病症和疾病。本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。还公开了使用抗体分子抑制或拮抗hIL-13Rα1介导的活性的方法。

6. 发明申请

WO2004105938A2 OXYDATION DU PROPANE EN ACIDE ACRYLIQUE PAR UTILISATION DE CATALYSEURS EN MELANGE DE PHASES CRISTALLINES 审中-公开
标题翻译：使用催化剂在结晶相混合物中丙烷氧化丙烯酸
公开(公告)号：WO2004105938A2
公开(公告)日：2004-12-09
申请号：PCT/FR2004/001290
申请日：2004-05-25
申请人： ATOFINA , DUBOIS, Jean-Luc , BACA, Manuel , MILLET, Jean-Marc
发明人： DUBOIS, Jean-Luc , BACA, Manuel , MILLET, Jean-Marc
IPC分类号： B01J23/00
CPC分类号： B01J23/28 , B01J23/002 , B01J23/18 , B01J23/20 , B01J27/0576 , B01J35/0006 , B01J2523/00 , C07C51/215 , C07C57/04 , B01J2523/55 , B01J2523/56 , B01J2523/64 , B01J2523/68 , B01J2523/53
摘要： Procédé de préparation de l'acide acrylique à partir de propane, dans lequel on fait passer un mélange gazeux comprenant du propane, de la vapeur d'eau, ainsi qu'éventuellement un gaz inerte et/ou de l'oxygène moléculaire, sur un catalyseur constitué d'une phase cristalline de catalyseur de formule (I) ou (I') Te a Mo l V b Nb c O x (I) Sb a 'Mo l V b O y (I') associée à une phase cristalline de catalyseur capable d'activer le propane.
摘要翻译：本发明涉及一种从丙烷生产丙烯酸的方法，其中包含丙烷，水蒸汽和任选的惰性气体和/或分子氧的气体混合物通过催化剂，其包含式（I）或（I'）TeaMolVbNbcOx（I）Sba Mol VbOy（I'），与用于活化丙烷的结晶催化剂相关。

7. 发明申请

WO2012171057A1 ANTIBODIES AGAINST G-CSFR AND USES THEREOF 审中-公开
标题翻译：抗G-CSFR的抗体及其用途
公开(公告)号：WO2012171057A1
公开(公告)日：2012-12-20
申请号：PCT/AU2012/000675
申请日：2012-06-13
申请人： CSL LIMITED , NASH, Andrew, Donald , ANDREWS, Arna Elizabeth , BACA, Manuel , EDWARDS, Kirsten Mae , HARDY, Matthew Philip , PANOUSIS, Con , DUNLOP, Felicity Meredith
发明人： NASH, Andrew, Donald , ANDREWS, Arna Elizabeth , BACA, Manuel , EDWARDS, Kirsten Mae , HARDY, Matthew Philip , PANOUSIS, Con , DUNLOP, Felicity Meredith
IPC分类号： C07K16/28 , A61K39/395 , A61P37/00
CPC分类号： C07K16/2866 , A61K2039/505 , A61K2039/545 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： The present disclosure provides proteins comprising antigen binding domains of antibodies that bind to human granulocyte-colony stimulating factor receptor.
摘要翻译：本公开提供了包含结合人粒细胞集落刺激因子受体的抗体的抗原结合结构域的蛋白质。

8. 发明申请

WO2003080675A3 MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1) 审中-公开
公开(公告)号：WO2003080675A3
公开(公告)日：2003-10-02
申请号：PCT/AU2003/000352
申请日：2003-03-21
申请人： AMRAD OPERATIONS PTY LTD , DUNLOP, Felicity, Meredith , BACA, Manuel , NASH, Andrew, Donald , FABRI, Louis, Jerry , HILTON, Douglas, James , NICOLA, Nicos, A.
发明人： DUNLOP, Felicity, Meredith , BACA, Manuel , NASH, Andrew, Donald , FABRI, Louis, Jerry , HILTON, Douglas, James , NICOLA, Nicos, A.
IPC分类号： C07K16/28 , C12N5/20 , A61K39/395
摘要： The present invention relates generally to antibodies that bind to the Interleukin-13 receptor α1 chain (IL-13Rα1) and antagonize IL-13 receptor-mediated signaling by IL-13 and/or IL-4. More particularly, the present invention provides humanized or human antibodies to mammalian and in particular IL-13Rα1. These antibodies have uses in the treatment or prevention of IL-13- and/or IL-4-mediated diseases or conditions. The present invention further contemplates a method of modulating IL-13- and/or IL-4-mediated diseases or conditions by the administration of the subject antibodies. The present invention further provides an assay system useful for identifying antibodies or other agents which modulate IL-13 and/or IL-4 signaling through an IL-13 receptor complex. Accordingly, a method of screening for modulators of IL-13Rα1/ligand interaction is also provided.

9. 发明申请

WO2008060813A2 HIGH AFFINITY ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR ALPHA 1 审中-公开
标题翻译：白细胞介素-13受体α1的高亲和力抗体拮抗剂
公开(公告)号：WO2008060813A2
公开(公告)日：2008-05-22
申请号：PCT/US2007/081879
申请日：2007-10-19
申请人： MERCK & CO., INC. , CSL LIMITED , NASH, Andrew, Donald , BACA, Manuel , FABRI, Louis, Jerry , ZALLER, Dennis , STROHL, William, R. , AN, Zhiqiang
发明人： NASH, Andrew, Donald , BACA, Manuel , FABRI, Louis, Jerry , ZALLER, Dennis , STROHL, William, R. , AN, Zhiqiang
IPC分类号： C07K16/18 , A61K39/395 , C12N15/11 , C12N15/00 , C12N5/06 , A61P43/00
CPC分类号： C07K16/2866 , C07K2317/21 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2319/43 , C12P21/005
摘要： High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rαl- mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rαl activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rαl-mediated activities are also disclosed.
摘要翻译：公开了人白细胞介素-13受体α1的高亲和力抗体拮抗剂。抗体分子在抑制IL-13Rα1介导的活性方面是有效的，因此，提供了用于治疗与hIL-13Rα1活性相关的病症的理想拮抗剂。本发明还公开了编码所述抗体分子，载体，宿主细胞和包含抗体分子的组合物的核酸。还公开了使用抗体分子抑制或拮抗IL-13Rα1介导的活性的方法。

10. 发明申请

WO2005030803A1 THERAPEUTIC MOLECULES 审中-公开
标题翻译：治疗分子
公开(公告)号：WO2005030803A1
公开(公告)日：2005-04-07
申请号：PCT/AU2004/001336
申请日：2004-09-29
申请人： THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH , BACA, Manuel , FAIRLIE, Walter, Douglas , UBOLDI, Alessandro, Dimitri
发明人： BACA, Manuel , FAIRLIE, Walter, Douglas , UBOLDI, Alessandro, Dimitri
IPC分类号： C07K14/52
CPC分类号： C07K14/5415 , A61K38/00
摘要： The present invention relates generally to Leukemia Inhibitory Factor (LIF) variants. More particularly, the present invention provides cytokine antagonists and agonists. Even more particularly, the present invention provides agonists and antagonists of cytokines which act via the Leukemia Inhibitory Factor (LIF) receptor a-chain (LIFR) and gp130 signalling system. The agonists and antagonists are based on modified forms of LIF. The agonists and antagonists of the present invention are also useful as targets for developing or screening for chemical mimetics and in particular small chemical mimetics of the modified LIF molecules. The agonists and antagonists of the present invention are useful agents in the treatment and/or prophylaxis of cytokine-mediated conditions including inflammation, cancer growth, fertility and pregnancy, or for the culturing of embryonic stem cells. The present invention further contemplates a method for modulating cytokine-mediated physiological or disease conditions such as inflammation, cancer, fertility or pregnancy as well as compositions comprising the antagonists.
摘要翻译：本发明一般涉及白血病抑制因子（LIF）变体。更具体地，本发明提供细胞因子拮抗剂和激动剂。更具体地，本发明提供通过白血病抑制因子（LIF）受体a链（LIFR）和gp130信号传导系统起作用的细胞因子的激动剂和拮抗剂。激动剂和拮抗剂是基于修饰形式的LIF。本发明的激动剂和拮抗剂也可用作开发或筛选化学模拟物，特别是修饰的LIF分子的小化学模拟物的靶标。本发明的激动剂和拮抗剂是治疗和/或预防细胞因子介导的病症（包括炎症，癌症生长，生育力和怀孕）或用于培养胚胎干细胞的有用试剂。本发明进一步考虑了调节细胞因子介导的生理或疾病状况如炎症，癌症，生育力或怀孕以及包含拮抗剂的组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式